Pharmaceutical Technology5d
Navocaftor by Sionna Therapeutics for Cystic Fibrosis: Likelihood of Approval
Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
GlobalData on MSN12d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
FiercePharma12d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Medscape11d
Cystic Fibrosis Transmembrane Conductance Regulator–Modifying Medications
combined groups: −5.4 mV (p < 0.001) CF = cystic fibrosis; FEV 1 = forced expiratory volume in 1 second. The classes of cystic fibrosis transmembrane conductance regulator (CFTR) mutations.
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.
Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand. Write to ...
Pharmaceutical Technology5d
SION-2851 by Sionna Therapeutics for Cystic Fibrosis: Likelihood of Approval
SION-2851 is under development for the treatment of cystic fibrosis. It is a small molecule administered orally. It is a first generation corrector. The drug candidate targets cystic fibrosis ...
Joplin Globe15d
Vertex Announces US FDA Approval of ALYFTREKâ„¢, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Announces US FDA Approval of ALYFTREKâ„¢, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis ...